Active Ingredient History
Icotinib is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Icotinib is approved for use in China as first-line monotherapy in patients with non-small-cell lung cancer with somatic EGFR mutations. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 4)
Adenocarcinoma of Lung (Phase 2)
Bevacizumab (Phase 3)
Brain Neoplasms (Phase 3)
Breast Neoplasms (Phase 2)
Bronchial Neoplasms (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 4)
Drugs, Investigational (Phase 3)
Epidermal Growth Factor (Phase 2)
Esophageal Neoplasms (Phase 2)
Esophageal Squamous Cell Carcinoma (Phase 2)
Lung Neoplasms (Phase 4)
Mutation (Phase 2/Phase 3)
Nasopharyngeal Carcinoma (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 3)
Neoplasms, Second Primary (Phase 4)
Neurofibromatosis 2 (Phase 2)
Neuroma, Acoustic (Phase 2)
Pancreatic Neoplasms (Phase 1)
Psoriasis (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue